Reducing empiricism in malaria vaccine design.

A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J (2012) 1.87

CD68 acts as a major gateway for malaria sporozoite liver infection. J Exp Med (2015) 1.47

The case for a rational genome-based vaccine against malaria. Front Microbiol (2015) 0.81

Synthesis of marine-derived 3-alkylpyridinium alkaloids with potent antiprotozoal activity. ACS Med Chem Lett (2011) 0.77

The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine (2010) 3.28

A review of vaccine research and development: meningococcal disease. Vaccine (2006) 2.64

Protein-protein interactions between hepatitis C virus nonstructural proteins. J Virol (2003) 2.23

A review of human vaccine research and development: malaria. Vaccine (2006) 1.95

First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine (2008) 1.71

The impact of globalization on vaccine development and availability. Health Aff (Millwood) (2006) 1.58

A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine (2006) 1.48

A review of vaccine research and development: human enteric infections. Vaccine (2005) 1.46

Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. Vaccine (2010) 1.29

A review of vaccine research and development: human acute respiratory infections. Vaccine (2005) 1.27

Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis (2009) 1.21

Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy. PLoS Negl Trop Dis (2012) 1.21

Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol (2006) 1.17

Global production capacity of seasonal influenza vaccine in 2011. Vaccine (2012) 1.17

Development and evaluation of influenza pandemic vaccines. Lancet Infect Dis (2006) 1.11

Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits. Vaccine (2008) 1.05

WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine (2011) 1.05

Secondary structure of the 3' terminus of hepatitis C virus minus-strand RNA. J Virol (2002) 0.94

Cholera in disasters: do vaccines prompt new hopes? Expert Rev Vaccines (2008) 0.92

Hepatitis C virus IRES efficiency is unaffected by the genomic RNA 3'NTR even in the presence of viral structural or non-structural proteins. J Gen Virol (2003) 0.92

Hepatitis C virus core, NS3, NS5A, NS5B proteins induce apoptosis in mature dendritic cells. J Med Virol (2005) 0.89

Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol (2002) 0.89

2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa--successes and challenges. J Infect Dis (2012) 0.88

Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets. Vaccine (2011) 0.87

Report of the third meeting on "influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization, Geneva, Switzerland, 3-4 December 2007. Vaccine (2008) 0.86

Development of vaccines against influenza H5. Lancet Infect Dis (2006) 0.86

Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009. Vaccine (2009) 0.86

Third meeting on Novel Adjuvants Currently in or Close to Clinical Testing World Health Organization--Organisation Mondiale de la Santé, Fondation Mérieux, Annecy, France, 7-9 January 2002. Vaccine (2003) 0.84

Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice. Cancer Gene Ther (2002) 0.83

Different approaches to influenza vaccination. N Engl J Med (2006) 0.83

The alpha-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step. Mol Pharmacol (2002) 0.82

Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine (2004) 0.81

Analysis of the subcellular localization of hepatitis C virus E2 glycoprotein in live cells using EGFP fusion proteins. J Gen Virol (2003) 0.79

The pandemic influenza vaccine challenge. Vaccine (2008) 0.78

European Union conference on poverty-related diseases research. Lancet Infect Dis (2009) 0.78

Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials." World Health Organization, Geneva, Switzerland, 14-15 February 2008. Vaccine (2008) 0.78

Immunization safety priority project at the World Health Organization. Semin Pediatr Infect Dis (2003) 0.77

Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005. Vaccine (2006) 0.77

Reboot biomedical R&D in the global public interest. Nature (2022) 0.75

Recombinant CD63/ME491/neuroglandular/NKI/C-3 antigen inhibits growth of established tumors in transgenic mice. J Immunol (2003) 0.75